738 results about "Disease cause" patented technology

Methods and kits are provided for diagnosing of neuropsychiatric syndromes concurrent with SLE (NPSLE) and for determining whether an SLE subject is at risk of developing a neuropsychiatric disease.

The invention provides an agricultural pest correlation analysis and diagnosis method and system based on a knowledge graph, and the method comprises the steps: firstly collecting a multi-source agricultural monitoring data set, including crop growth stage parameters, meteorological fluctuation parameters and the like, of a target region, and then processing meteorological and soil humidity parameters through an environment feature extraction model to generate a multi-dimensional environment feature set; processing disease and pest symptom image data by using a symptom feature extraction model to generate a symptom feature set, calculating dynamic correlation degree parameters of the two based on a knowledge graph topological structure, constructing a disease and pest cause probability distribution diagram, and then performing joint reasoning on crop growth stage parameters and the cause probability distribution diagram by using a pre-trained disease and pest diagnosis model to obtain a disease and pest disease diagnosis result. And finally, matching an optimal control strategy set according to the multi-level disease and insect pest diagnosis results, and inputting the optimal control strategy set into an agricultural decision-making system to trigger control equipment regulation and control operation, thereby realizing scientific and effective disease and insect pest diagnosis and control.

The invention discloses application of an OsMYB23 gene in improving resistance of rice to ustilaginoidea virens, and belongs to the technical field of gene engineering. The nucleotide sequence of the CDS region of the OsMYB23 gene is as shown in SEQ ID NO. 2. Researches find that the OsMYB23 gene is related to the resistance of rice to the false smut, the over-expression of the OsMYB23 gene significantly reduces the disease resistance of the rice to the false smut, the mutation of the OsMYB23 gene improves the defense capability of the rice to the false smut, and the mutation of the OsMYB23 gene does not influence the normal growth of the rice, so that the OsMYB23 gene of the rice can be used for improving the resistance of the rice to the false smut, and the rice can be used for preparing the rice for preventing and treating the false smut. And a theoretical basis is provided for prevention and control of rice ustilaginoidea virens and diseases caused by the rice

The invention relates to antiviral application of a membrane fusion inhibition polypeptide. The membrane fusion inhibition polypeptide is used for treating diseases caused by virus infection of pneumoviridae.

The invention discloses enterobacter mori capable of resisting fish aeromonas and application of the enterobacter mori, the bacterial strain is classified and named as enterobacter mori SCH0241, the enterobacter mori SCH0241 is preserved in the China Center for Type Culture Collection on October 17, 2024, and the preservation number is CCTCC NO: M 20242236. The enterobacter mori SCH0241 disclosed by the invention is derived from the intestinal tract of high-stress-resistance healthy hybrid crucian carassius auratus No. 2, has good contact dependence antibacterial activity on aeromonas veronii, and can improve the capability of resisting aeromonas veronii infection of zebra fish. Through construction of an insertion mutation library and phenotype screening, it is found that a gene cluster of SCH0241, which exerts contact inhibition toxicity, is T6SS-2. The enterobacter mori SCH0241 disclosed by the invention provides a new powerful tool for biological prevention and treatment of fish diseases caused by aeromonas veronii.

The present invention has an object of providing a composition that is effective for the treatment of a prototheca disease. According to the present invention, a composition containing ravuconazole as an active ingredient, which is administered to an animal suffering from a prototheca disease caused by Prototheca wickerhamii or Prototheca zopfii, is provided.

The invention belongs to the technical field of biology, and particularly relates to an anti-porcine reproductive and respiratory syndrome virus antibody or an antigen binding fragment thereof and application thereof. The antibody or the antigen binding fragment thereof can specifically recognize and bind the porcine reproductive and respiratory syndrome virus or the GP4 protein thereof, and has good affinity with the porcine reproductive and respiratory syndrome virus or the GP4 protein thereof; the compound can be used for preparing products for diagnosing, preventing and / or treating porcine reproductive and respiratory syndrome virus infection or diseases caused by porcine reproductive and respiratory syndrome virus infection, detecting existence or level of porcine reproductive and respiratory syndrome virus or GP4 protein thereof in a sample or screening drugs for preventing and / or treating porcine reproductive and respiratory syndrome virus infection or diseases caused by porcine reproductive and respiratory syndrome virus infection.

The invention relates to the technical field of microorganisms, in particular to a citrobacter welchii bacteriophage as well as a composition and application thereof. The name of the citrobacter werkmanii bacteriophage is RDP-CI25012, the citrobacter werkmanii bacteriophage is preserved in the general microbiological center of the China Committee for Culture Collection of Microorganisms on August 25, 2025, and the preservation number of the citrobacter werkmanii bacteriophage is CGMCC (China General Microbiological Culture Collection Center) No. 46668. The composition comprises the bacteriophage. The bacteriophage or the composition is prepared in the following steps: (1) preparing a product for killing citrobacter welchii; (2) preparing a product for inhibiting citrobacter welchii; and (3) application in preparation of a product for preventing and / or treating citrobacter welchii disease caused by citrobacter welchii. The cracking rate of the phage is 80%, and the phage has an extremely high host range and a relatively wide cracking spectrum. After the bacteriophage is treated at 50 DEG C for 4 hours, the titer is still kept at 107 PFU / mL or above, and the bacteriophage has excellent thermal stability, so that a solid foundation is laid for use, storage, transportation and production processing of the bacteriophage in most practical application scenes.

The invention provides an application of nigericin in preparation of an anti-PRRSV (Porcine Reproductive and Respiratory Syndrome Virus) drug, and belongs to the technical field of antiviral drugs. Experimental results show that the nigericin has extremely remarkable inhibiting and blocking effects on a 1-bit ribosome framing process of the PRRSV virus, and can be used for effectively inhibiting the replication of the PRRSV virus so as to inhibit the proliferation of the PRRSV virus; in addition, the compound has an extremely remarkable inhibition effect on the frame shift process of-1-bit ribosomes of different strains of PRRSV viruses; the nigericin can effectively inhibit replication and proliferation of PRRSV in vitro and in vivo of live pigs, can be used for preparing products for inhibiting proliferation of the PRRSV and can be used for preparing drugs for treating and preventing diseases caused by PRRSV infection, and the drugs are broad-spectrum anti-PRRSV drugs and have wide application prospects.

The invention relates to a nanoparticle system for small intestine delivery, which is used for delivering exogenous miR-122-5p to the intestinal tract and comprises a miRNA-protamine compound inner core, a liposome middle layer wrapping the inner core and a p123 functional shell wrapping the liposome. Due to the adoption of the technical scheme, a nano-targeting delivery technology is combined with paternal epigenetic programming intervention for the first time, and a brand-new nano-drug treatment thought is provided for intergenerational genetic diseases caused by exposure of environmental adverse factors. By delivering exogenous miR-122-5p to the intestinal tract, the miRNA spectrum unbalanced due to exposure of paternal BaP can be directly improved.

The invention relates to application of a plant-derived extracellular vesicle and a compound thereof in preparation of a pharmaceutical composition for treating or preventing diseases caused by high colonization degree of gram-positive bacteria in skin, in particular to application of a purslane extracellular vesicle and a compound of the purslane extracellular vesicle and hydrogel.

A road disease duplicate removal method based on improved TransTrack and disease continuous frame number estimation belongs to the field of intelligent traffic, and comprises the following steps: S1, vehicle-mounted video data acquisition: adopting a vehicle-mounted camera to acquire road video data; s2, image preprocessing: extracting a region of interest of the image and performing image enhancement processing; s3, road disease detection and tracking: detecting and continuously tracking the road disease by using an improved TransTrack model; s4, calculating the number of disease existing frames: estimating the number of frames experienced by each disease object from the first occurrence to the final disappearance; and S5, disease de-weighting: extracting the clearest frame of the same ID disease before the disease disappears, and realizing de-weighting. According to the method, automatic tracking and duplicate removal of road diseases are realized, the problem of repeated statistics of the same disease caused by continuous shooting of a vehicle-mounted camera is effectively solved, and the completeness of disease information is ensured by extracting the clearest frame.

The invention belongs to the technical field of biology, and particularly relates to an anti-porcine reproductive and respiratory syndrome virus antibody as well as a preparation method and application thereof. The antibody or the antigen binding fragment thereof can specifically recognize and bind the porcine reproductive and respiratory syndrome virus or the GP4 protein thereof, and has good affinity with the porcine reproductive and respiratory syndrome virus or the GP4 protein thereof; the compound can be used for preparing products for diagnosing, preventing and / or treating porcine reproductive and respiratory syndrome virus infection or diseases caused by porcine reproductive and respiratory syndrome virus infection, detecting existence or level of porcine reproductive and respiratory syndrome virus or GP4 protein thereof in a sample or screening drugs for preventing and / or treating porcine reproductive and respiratory syndrome virus infection or diseases caused by porcine reproductive and respiratory syndrome virus infection.

The invention discloses a hepatocellular carcinoma prognosis and immune response prediction method based on multi-omics machine learning, and relates to the technical field of biomedicine and artificial intelligence crossing, and the method comprises the following steps: S1, constructing a multi-omics data set for model training and verification; s2, performing feature integration and clustering analysis on the multi-omics data to obtain corresponding hepatocellular carcinoma molecular subtype distribution; s3, constructing a hepatocellular carcinoma prognosis model based on Cox regression combined with a random survival forest, identifying 11 core immune genes and corresponding weight coefficients by training the model, and constructing an immunotherapy response index IMLIRI score; and S4, carrying out clinical application on the IMLIRI score. According to the method, through multi-omics data integration and multi-queue external verification, the influence of data deviation and queue heterogeneity on the model performance is reduced, so that the method shows stable prediction performance in hepatocellular carcinoma queues with different sources and different pathogenesis backgrounds, and the reliability and generalizability of the model in clinical application are improved.

HPV16 is a main cause of malignant tumors such as cervical cancer, and E6 protein of HPV16 becomes a key treatment and diagnosis target. In the prior art, an HPV16 detection antibody has the problems of poor stability, dependence on cold chain transportation, low preparation efficiency and the like. According to the invention, a nano antibody sequence which is high in affinity (dissociation constant KD is less than or equal to 1 * 10 <-7 > M) and stable at room temperature is obtained through total synthesis library construction and a phage-assisted directed evolution (PACE) screening technology. After the antibody is stored at 25 DEG C for 30 days, the activity of the antibody is kept to be greater than or equal to 95%, the antibody can be directly used for household test paper, the accuracy rate reaches 98%, and meanwhile, the antibody can be expanded to medical applications such as CAR-T cell therapy. Compared with a traditional antibody, the antibody has the advantages of being short in preparation period, low in cost, wide in application scene and the like, and a breakthrough solution is provided for early screening of cervical cancer.

A personalized medical method for treating amyotrophic lateral sclerosis (ALS), comprising screening out a subpopulation of ALS patients having highly immunologically active causes, and administering a therapeutically effective amount of a Janus kinase (JAK) inhibitor to the patients screened out thereby. Also provided are the use of a corresponding JAK inhibitor, an in vitro diagnostic method for screening patients, a kit, and a computer-implemented method. After patients screened out by means of the method are treated with a JAK inhibitor (such as tofacitinib), the level of a nerve damage marker is significantly reduced, and clinical functions are stabilized or improved, and therefore the present invention shows a good therapeutic prospect.

The present application provides the use of raltitrexed in the manufacture of a medicament for the treatment of diseases caused by adenovirus infection, including but not limited to respiratory tract infection, gastrointestinal infection and keratitis caused by adenovirus. When raltitrexed was tested for its anti-adenovirus activity at the cellular level, using a viral infection dose of 100 TCID50, the viral infectivity was determined on a human non-small cell lung cancer cell line (A549 cell) model, and the results showed that raltitrexed had a significant inhibitory effect on adenovirus, with an EC 50 = 8.98 nM, a CC 50 > 187.5 nM, and it was found that it had a significant inhibitory effect on the entry of the virus into the cell; and in the hDSG2 mouse model, a significant inhibitory effect of raltitrexed on viral replication was also observed. Therefore, raltitrexed can be used to treat diseases caused by adenovirus infection.

The peptides of the present invention exhibit skin whitening activity by inhibiting melanin synthesis in melanocytes and inhibiting melanin body migration. Therefore, the peptide of the present invention can be used as an active ingredient in a medicament for treating or preventing hyperpigmentation diseases caused by excessive deposition of melanin bodies, or as an active ingredient in a cosmetic for skin whitening.

It discloses a method for the treatment of disease caused by HIV infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound (1) or a pharmaceutically acceptable salt thereof.

Provided is a CFB-targeting double-stranded RNA molecule, specifically an siRNA. The provided siRNA can effectively inhibit the CFB expression, and can be used for preventing and treating diseases caused by up-regulated CFB expression or diseases associated with abnormal activation of an alternative complement pathway.

The application belongs to the field of biological medicine, and particularly relates to a medicine for blue ear virus. The application mainly provides a medicine combination based on polyether long-chain antibiotics, which is used for treating and / or preventing a disease caused by a porcine reproductive and respiratory syndrome virus (PRRSV). The medicine of the application can efficiently inhibit the replication of the PRRSV, helps to maintain the health state and production performance of pigs, has a simple preparation method, is suitable for large-scale production, and provides a new and effective solution for the animal husbandry.

The invention provides an azacycloalkane compound as shown in a formula I, pharmaceutically acceptable salt, hydrate, isomer, prodrug or a mixture thereof, a pharmaceutical composition containing the azacycloalkane compound, and application of the azacycloalkane compound and the pharmaceutically acceptable salt, hydrate, isomer, prodrug or the mixture thereof in preparation of drugs for preventing, relieving or treating related diseases caused by interaction with Menin-MLL protein.

The application discloses the use of carbon cyanogen - 4 trifluoromethoxy benzyl hydrazone in the prevention and treatment of candida infection, belonging to the technical field of candida infection prevention and treatment. Carbon cyanogen - 4 trifluoromethoxy benzyl hydrazone is used as the only active ingredient for preparing a medicine for preventing or treating diseases caused by candida infection, wherein the candida is candida albicans and / or candida auris; or it is used for preparing a bacteriostatic and / or bactericidal product of candida, wherein the candida is candida albicans and / or candida auris. FCCP shows good inhibition of strain growth, good inhibition of biofilm effect and good mitochondria breaking effect in the antibacterial experiments of various candida (wild type candida albicans, drug resistant candida albicans and drug resistant candida auris). Thus, a new treatment drug for candida albicans and candida auris infection is provided.

Vaccine compositions for protecting a subject against diseases caused by viral pathogens of the Picornaviridae family are disclosed. These vaccines comprise nucleic acids encoding the capsid polyprotein (P1 polyprotein) mixed with the viral 3C protease that processes the P1 polyprotein, and encapsulated within nanoparticle carriers. Methods of preventing, reducing, inhibiting, or delaying the symptoms of an infection caused by a viral pathogen, or of inducing an immune response against a viral pathogen in a subject are provided. Methods of making the vaccines are also described.

The application belongs to the technical field of biotechnology, and particularly relates to a human metapneumovirus mouse-adapted strain and application thereof. Compared with wild strains, the strain can exhibit stronger susceptibility to animals, and can cause typical clinical symptoms and even death. For example, after the strain infects BALB / c mice, the disease symptoms are obvious, 83% of the mice have a severe decrease in body weight to below 75% after infection, and have reached the humane killing standard. Four days after the strain infects BALB / c mice, the mortality rate is above 50%. The strain can be used to construct a cell model or an animal model of human metapneumovirus infection or a disease caused by the human metapneumovirus, and is further used to screen drugs for preventing and / or treating human metapneumovirus infection or a disease caused by the human metapneumovirus. In addition, the strain can also be used to prepare drugs for preventing and / or treating human metapneumovirus infection or a disease caused by the human metapneumovirus, and to prepare antibodies or antisera against the human metapneumovirus.

The present disclosure relates to a nucleoside analogue and a use thereof. The nucleoside analogue is a compound shown in formula (Ia) or a prodrug thereof. The nucleoside analogue can enhance targeted delivery of oligonucleotide drugs to nervous system cells, thereby increasing the inhibition rate of the oligonucleotide drugs delivered in a targeted manner on expression of specific genes in the nervous system cells, or enabling the oligonucleotide drugs delivered in a targeted manner to achieve the purpose of preventing and / or treating pathological conditions or diseases caused by abnormal expression of the specific genes in the nervous system cells. The present disclosure also relates to a nucleotide analogue-containing double-stranded oligonucleotide and a use thereof. The double-stranded oligonucleotide comprises a sense strand and an antisense strand, each strand has 17-25 modified and / or unmodified nucleotides, and the antisense strand and the sense strand are complementary to form a duplex region; the sense strand and / or the antisense strand contains at least one nucleotide analogue represented by the structure of formula (100), or a tautomer, or stereoisomer, or pharmaceutically acceptable salt thereof; the double-stranded oligonucleotide can effectively treat and / or prevent pathological conditions or diseases caused by abnormal expression of specific genes in nervous system cells.

The present invention relates to a pyrazine macrolide compound and the use thereof. Specifically disclosed is a compound as represented by formula I or a pharmaceutically acceptable salt thereof. The compound of the present invention exhibits activity against bacteria, mycoplasmas, or chlamydias, and is useful for preventing and / or treating diseases caused by bacteria, mycoplasmas, or chlamydias. Further, the compound of the present application can achieve an antibacterial activity comparable to or better than that of azithromycin or solithromycin at a lower dosage. Furthermore, the compound of the present application achieves a superior antibacterial effect on Gram-positive bacteria. Still furthermore, the compound of the present application exhibits a better inhibitory activity against mycoplasmas and a lower hepatotoxicity.

The embodiment of the invention provides a clinical intervention decision-making method and device, electronic equipment and a storage medium, and belongs to the technical field of artificial intelligence. The method comprises the steps that secretory otitis media clinical data of a to-be-evaluated user are acquired, and the secretory otitis media clinical data comprise multiple etiological clinical features; obtaining a target secretory otitis media disease probability prediction model; on the basis of a target secretory otitis media disease probability prediction model, performing feature evaluation on the clinical features of the multiple etiologies to obtain multiple user feature scores; based on the target secretory otitis media disease probability prediction model and the plurality of user feature scores, performing disease probability prediction on the to-be-evaluated user to obtain user disease prediction data; and based on the user disease prediction data, performing clinical intervention decision on the to-be-evaluated user. According to the application, the secretory otitis media can be effectively prevented, the accuracy of clinical intervention decisions can be improved, and in addition, the treatment effect of the secretory otitis media can be effectively evaluated.

The invention relates to the technical field of biological medicines, and discloses application of INHBC as a target spot in prevention and / or treatment of metabolic diseases. Specifically, the invention relates to application of substances for promoting INHBC gene expression or improving protein activity in preparation of products for preventing and / or treating metabolic diseases, and the metabolic diseases comprise diseases caused by energy metabolism disorder, such as obesity, diabetes, fatty liver disease, hyperlipidemia and the like. According to the application disclosed by the invention, liver specific overexpression or INHBC knock-in can improve mouse liver fatty degeneration and abnormal glucose metabolism induced by high fat diet, and in addition, the heat production activity of mouse adipose tissues can be enhanced, so that obesity induced by high fat diet is inhibited; the compound has an important application value in preventing and / or treating metabolic diseases such as obesity, type 2 diabetes and fatty liver diseases.

The invention provides application of periplocin in preparation of anti-PRRSV (Porcine Reproductive and Respiratory Syndrome Virus) drugs, and belongs to the technical field of antiviral drugs. Experimental results show that periplocin has extremely remarkable inhibiting and blocking effects on a 1-bit ribosome framing process of the PRRSV virus, and can be used for effectively inhibiting the replication of the PRRSV virus so as to inhibit the proliferation of the PRRSV virus; in addition, the compound has an extremely remarkable inhibition effect on the frame shift process of-1-bit ribosomes of different strains of PRRSV viruses; the periplocin can effectively inhibit replication and proliferation of PRRSV in vitro and in vivo of live pigs, can be used for preparing products for inhibiting proliferation of the PRRSV and can be used for preparing drugs for treating and preventing diseases caused by PRRSV infection, and the drugs are broad-spectrum anti-PRRSV drugs and have wide application prospects.